ARIAD ANNOUNCES INITIAL DATA ON AP26113, INVESTIGATIONAL DUAL-INHIBITOR OF ALK AND EGFR, TO BE PRESENTED AT THE ESMO 2012 CONGRESS OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

September 17, 2012

~ Data from Dose-escalation Portion of Ongoing Phase 1/2 Clinical Trial to be Presented on Saturday, September 29 at 11:15 a.m. (CEST)

~ Company to Host Investor Call and Webcast with Dr. Scott Gettinger on Monday, October 1, 2012 at 8:00 a.m. (ET)

Cambridge, MA, September 17, 2012 -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the initial data from its Phase 1/2 trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), will be presented at the ESMO 2012 Congress of the European Society for Medical Oncology (ESMO) being held in Vienna, Austria, September 28 to October 2, 2012. 

Results from the dose-escalation portion of the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 29, 2012 and will also be highlighted in a company-sponsored investor conference call to be webcast live from Vienna. 

The schedule and meeting location for the session, together with the abstract information and details on the investor briefing, are listed below:

Oral Presentation at ESMO

Title:             A First-in-Human Dose-Finding Study of the ALK/EGFR Inhibitor AP26113 in Patients with Advanced Malignancies

Oral Session:            Development Therapeutics Session

Date & Time:    Saturday, September 29, 11:15 a.m. (CEST)

Abstract No:    4390  

Presenter:    Scott Gettinger, M.D. (Yale University School of Medicine)

Location:    Hall

Investor Webcast

ARIAD will hold an investor conference call and webcast on Monday, October 1, 2012, at 8:00 a.m. ET to discuss the data from the ongoing Phase 1/2 trial of AP26113. Scott Gettinger, M.D., Associate Professor of Medicine at Yale University School of Medicine, will join members of ARIAD’s management team for the briefing from Vienna. This call will be webcast live and can be accessed by visiting the investor relations section of ARIAD’s website at: http://investor.ariad.com or by dialing 1-866-700-0161 (domestic) or 617-213-8832 (international) five minutes prior to the start time and providing the pass code 50829176.

A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients.  ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer.  For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.